Literature DB >> 21484863

Rapidly progressive diffuse Lewy body disease.

Carles Gaig1, Francesc Valldeoriola, Ellen Gelpi, Mario Ezquerra, Sara Llufriu, Mariateresa Buongiorno, Maria Jesús Rey, Maria Jose Martí, Francesc Graus, Eduardo Tolosa.   

Abstract

BACKGROUND: Lewy body syndromes (mainly Parkinson's disease and dementia with Lewy bodies) share many clinical features and usually have a slowly progressive course. Some patients may show rapid symptoms progression.
OBJECTIVE: To evaluate clinical and neuropathological features of patients with a rapidly progressive diffuse Lewy Body disease.
METHODS: Review clinical records and pathological findings of 6 cases with diffuse Lewy Body disease and rapid disease progression (less than 18 months before death).
RESULTS: Mean age at disease onset was 72.5 years, and mean disease duration was 9 months. Onset consisted of delirium in 3 patients and rapidly progressive dementia in the other three. All cases presented visual hallucinations and delusions; cognitive symptoms were fluctuating in two, parkinsonism occurred in four, and myoclonus in three. Brain MRI did not show cortical or basal ganglia hyperintensities. Periodic sharp waves were absent on EEG. 14.3.3 protein in CSF was negative. Myocardial (123) I-metaiodo-benzyl-guanidine SPECT showed marked reduction in tracer uptake in the 2 patients tested. Neuropathological studies did not identify any particular feature that could differentiate rapidly progressive diffuse Lewy body disease from classical diffuse Lewy body disease.
CONCLUSIONS: Diffuse Lewy body disease is a possible cause of rapidly progressive dementia and should be included in the differential diagnosis of confusional states of undetermined cause. In patients with rapidly progressive dementia, the presence of fluctuating cognition, parkinsonism, hallucinations, delusions, or severe dysautonomia, should raise the suspicion of diffuse Lewy body disease. Neuroimaging studies such as (123) I-metaiodo-benzyl-guanidine myocardial scintigraphy may support the clinical diagnosis of diffuse Lewy body disease. © 2011 Movement Disorder Society.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21484863     DOI: 10.1002/mds.23506

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

Review 1.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

Review 2.  Neuroimaging of rapidly progressive dementias, part 1: neurodegenerative etiologies.

Authors:  A J Degnan; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-02-22       Impact factor: 3.825

Review 3.  A clinicopathological approach to the diagnosis of dementia.

Authors:  Fanny M Elahi; Bruce L Miller
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 4.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

5.  Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease.

Authors:  Maria Carmela Tartaglia; David Y Johnson; Julie Ngoc Thai; Tatiana Cattaruzza; Katherine Wong; Paul Garcia; Stephen J Dearmond; Bruce L Miller; Michael D Geschwind
Journal:  Can J Neurol Sci       Date:  2012-05       Impact factor: 2.104

6.  α-Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders.

Authors:  Ivan Martinez-Valbuena; Emily Swinkin; Enrique Santamaria; Joaquin Fernandez-Irigoyen; Valerie Sackmann; Ain Kim; Jun Li; Paulina Gonzalez-Latapi; Greg Kuhlman; Suvorit Subhas Bhowmick; Naomi P Visanji; Anthony E Lang; Gabor G Kovacs
Journal:  Acta Neuropathol       Date:  2022-06-24       Impact factor: 15.887

7.  A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD.

Authors:  Swati Haldar; 'alim J Beveridge; Joseph Wong; Ajay Singh; Daniela Galimberti; Barbara Borroni; Xiongwei Zhu; Janis Blevins; Justin Greenlee; George Perry; Chinmay K Mukhopadhyay; Christine Schmotzer; Neena Singh
Journal:  Antioxid Redox Signal       Date:  2013-04-16       Impact factor: 8.401

8.  Clinico-pathological correlations of the most common neurodegenerative dementias.

Authors:  Ricardo Taipa; João Pinho; Manuel Melo-Pires
Journal:  Front Neurol       Date:  2012-05-01       Impact factor: 4.003

9.  Rapidly progressive dementia with thalamic degeneration and peculiar cortical prion protein immunoreactivity, but absence of proteinase K resistant PrP: a new disease entity?

Authors:  Gabor G Kovacs; Alexander Peden; Serge Weis; Romana Höftberger; Anna S Berghoff; Helen Yull; Thomas Ströbel; Stefan Koppi; Regina Katzenschlager; Dieter Langenscheidt; Hamid Assar; Elisabeth Zaruba; Albrecht Gröner; Till Voigtländer; Gina Puska; Eva Hametner; Astrid Grams; Armin Muigg; Michael Knoflach; Lajos László; James W Ironside; Mark W Head; Herbert Budka
Journal:  Acta Neuropathol Commun       Date:  2013-11-11       Impact factor: 7.801

10.  Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study.

Authors:  Kajsa Stubendorff; Victoria Larsson; Clive Ballard; Lennart Minthon; Dag Aarsland; Elisabet Londos
Journal:  BMJ Open       Date:  2014-07-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.